Codex DNA, Inc. (DNAY)

Codex DNA, Inc. (DNAY) Healthcare & Pipeline Overview

Codex DNA, Inc. operates in the synthetic biology sector, providing automated benchtop instruments like the BioXp system, reagents, and Biofoundry Services for DNA and mRNA synthesis. The company serves global pharmaceutical, academic, and government clients, positioning itself as a key enabler for accelerating drug discovery and biomanufacturing processes.

What Is the Investment Thesis for DNAY?

Codex DNA, Inc. is positioned within the growing synthetic biology market, offering automated solutions for DNA and mRNA synthesis crucial for drug discovery and biomanufacturing. The company's BioXp system and Biofoundry Services address the increasing demand for rapid, high-throughput genetic material production, a key value driver. With a gross margin of 61.6%, the company demonstrates strong unit economics on its product sales. Growth catalysts include the potential expansion of its global customer base across pharmaceutical, academic, and government sectors, driven by the efficiency and scalability of its proprietary technology. The ongoing need to accelerate research and development timelines in biopharma presents a sustained demand for Codex DNA's offerings. However, the company faces significant challenges, as evidenced by its -173.5% profit margin and a relatively small market capitalization of $38.32M, indicating a need to achieve profitability. Risks include intense competition from established players in the genomics and life sciences industries and the imperative to continuously innovate and expand its market penetration to achieve sustainable financial performance. Investors should monitor the company's ability to convert its high gross margin into overall profitability and secure a larger share of the evolving synthetic biology market.

Based on FMP financials and quantitative analysis

DNAY Key Highlights

• Market capitalization stands at $0.04 billion, reflecting its current valuation within the synthetic biology sector.
• The company reported a gross margin of 61.6%, indicating strong profitability on its core product and service sales before operating expenses.
• Codex DNA, Inc. currently operates with a profit margin of -173.5%, highlighting significant operational losses relative to its revenue.
• The company does not pay a dividend, consistent with many growth-focused biotechnology firms reinvesting earnings.
• It employs 212 individuals, supporting its research, development, manufacturing, and sales operations globally.

Who Are DNAY's Competitors?

DNAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DNAY's Key Strengths?

• Proprietary BioXp system offers automated, rapid DNA and mRNA synthesis, accelerating research.
• Diverse product portfolio including instruments, reagents (Gibson Assembly), software, and Biofoundry Services.
• Broad customer base spanning pharmaceutical, academic, government, and CRO sectors globally.
• Strong gross margin of 61.6% on product and service sales.

What Are DNAY's Weaknesses?

• Significant negative profit margin (-173.5%), indicating ongoing operational losses.
• Relatively small market capitalization ($0.04 billion), suggesting limited financial scale.
• Dependence on a rapidly evolving synthetic biology market, requiring continuous innovation.
• Need to expand customer base and achieve profitability in a competitive market.

What Could Drive DNAY Stock Higher?

• Introduction of new BioXp system capabilities or specialized kits that expand application areas, potentially driving increased instrument and reagent sales.
• Expansion of the global customer base, particularly securing new contracts with major pharmaceutical firms or large academic consortia, demonstrating market penetration.
• Achievement of significant milestones in biomanufacturing partnerships, showcasing the BioXp system's scalability and efficiency for industrial applications.
• Strategic initiatives aimed at improving operational efficiency and cost management, which could lead to a reduction in the company's negative profit margin.

What Are the Key Risks for DNAY?

• Financial-distress signal — its Altman Z-Score of -12.80 sits in the distress zone (elevated bankruptcy risk).
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
• Intense competition from established players in the genomics and life sciences industries, which possess greater financial resources and market presence.
• Failure to achieve profitability, as indicated by the current -173.5% profit margin, which could impact long-term sustainability and access to capital.
• Rapid technological advancements by competitors or the emergence of disruptive technologies that could diminish the competitive advantage of the BioXp system.
• Dependence on R&D budgets of pharmaceutical and academic institutions, making the company susceptible to shifts in research funding or economic downturns.
• Challenges in expanding the customer base sufficiently to offset high operating costs and achieve economies of scale in manufacturing and service delivery.

What Are the Growth Opportunities for DNAY?

• **Expansion in Drug Discovery Acceleration:** The global pharmaceutical industry is under constant pressure to reduce drug discovery timelines and costs. Codex DNA's BioXp system, which automates the synthesis of DNA and mRNA, offers a significant advantage by rapidly generating genetic constructs needed for target validation, lead optimization, and preclinical studies. This automation can dramatically shorten the early-stage R&D cycle. The market for drug discovery technologies is projected to grow substantially, driven by increasing R&D investments and the complexity of new therapeutic modalities. By continuously enhancing the BioXp system's capabilities and expanding its integration into existing drug discovery workflows, Codex DNA can capture a larger share of this high-value market, potentially leading to increased instrument sales and Biofoundry Service contracts.
• **Penetration into Biomanufacturing:** The biomanufacturing sector, encompassing the production of biologics, vaccines, and cell and gene therapies, relies heavily on efficient and scalable genetic engineering. Codex DNA's technology can play a crucial role in optimizing cell lines, producing viral vectors, and synthesizing mRNA for vaccine development and therapeutic applications. The global biomanufacturing market is experiencing robust growth, fueled by the expanding pipeline of biological drugs and the demand for faster production cycles. By demonstrating the scalability and reliability of its synthetic biology tools for industrial-scale applications, Codex DNA has a substantial opportunity to become a preferred partner for biopharmaceutical companies seeking to streamline their production processes and accelerate time-to-market for novel therapies.
• **Broadening Customer Base in Academic and Government Research:** While pharmaceutical firms are a primary focus, academic laboratories and government institutions represent a vast and continuously funded segment for synthetic biology tools. These entities are at the forefront of basic research, disease understanding, and public health initiatives, requiring flexible and efficient DNA/mRNA synthesis capabilities. Codex DNA can expand its market penetration by offering tailored solutions, educational programs, and competitive pricing structures to these institutions. The ongoing need for rapid prototyping of genetic constructs for various research projects, from fundamental biology to applied research in areas like infectious disease surveillance, provides a sustained demand. Expanding this customer base globally, particularly in emerging research hubs, offers a significant avenue for revenue growth for instruments, reagents, and Biofoundry Services.
• **Development of New Applications for Synthetic Biology:** The field of synthetic biology is continuously evolving, with new applications emerging in areas like sustainable chemicals, agriculture, and advanced materials. Codex DNA's core technology, capable of synthesizing custom DNA and mRNA, is foundational to many of these nascent industries. By investing in R&D and collaborating with innovators in these sectors, the company can identify and develop new kits, protocols, or Biofoundry Service offerings that cater to these specialized needs. This proactive approach to application development allows Codex DNA to tap into future growth markets beyond its current focus on healthcare, potentially unlocking entirely new revenue streams and diversifying its operational footprint.
• **Leveraging Biofoundry Services for Outsourcing Trends:** The trend towards outsourcing specialized scientific services is growing, particularly among smaller biotech firms or larger organizations looking to optimize internal resources. Codex DNA's Biofoundry Services, which provide endpoint-ready BioXp products and enzymatic DNA synthesis, directly address this market need. By offering a comprehensive service model, the company can attract clients who prefer to commission genetic constructs rather than invest in instruments and personnel. This service-based approach provides a recurring revenue stream and allows Codex DNA to serve a broader range of clients, including those with intermittent or highly specialized synthesis requirements. Expanding the capacity and breadth of these services, potentially through strategic partnerships, represents a significant growth opportunity in the evolving landscape of contract research and manufacturing.

What Opportunities Does DNAY Have?

• Increasing global demand for synthetic biology tools in drug discovery and biomanufacturing.
• Expansion into new therapeutic areas or applications for its DNA/mRNA synthesis technology.
• Growth of the outsourcing trend in scientific services, benefiting Biofoundry Services.
• Potential for strategic partnerships or collaborations to broaden market reach and technology integration.

What Threats Does DNAY Face?

• Intense competition from established players in the genomics and life sciences industries.
• Rapid technological obsolescence requiring continuous R&D investment.
• Regulatory changes impacting genetic engineering and synthetic biology products.
• Economic downturns potentially reducing R&D budgets of key customers.

What Are DNAY's Competitive Advantages?

• Proprietary BioXp system, an automated benchtop instrument for rapid DNA and mRNA synthesis, offering a unique value proposition.
• Exclusive Gibson Assembly brand, a widely recognized and utilized method for seamless DNA assembly, integrated into its kits.
• Comprehensive Biofoundry Services, providing end-to-end custom synthesis solutions that reduce client's need for in-house expertise and equipment.
• Integrated ecosystem of instruments, reagents, software (BioXp portal), and services, creating a sticky customer experience and workflow.

What Does DNAY Do?

Codex DNA, Inc., established in 2011 and headquartered in San Diego, California, is a pivotal player in the synthetic biology sector. Initially known as SGI-DNA, Inc., the company rebranded in March 2020, marking its evolution and expanded focus. Codex DNA specializes in the development, manufacturing, and sale of advanced instruments, reagents, and comprehensive complementary services designed to streamline and accelerate genetic research and development. Its core offering, the BioXp system, is an innovative benchtop instrument capable of transforming digital DNA sequences into usable synthetic DNA, significantly reducing the time and manual effort traditionally associated with gene synthesis. This system is complemented by the intuitive BioXp portal, an online platform that empowers researchers to design and assemble DNA sequences into chosen vectors with ease. To support diverse synthetic biology applications, Codex DNA also provides BioXp kits, which include essential building blocks and reagents, notably featuring the proprietary Gibson Assembly brand, renowned for its efficient DNA assembly capabilities. Beyond instrumentation and consumables, the company extends its support through cloud-based scripts and specialized benchtop reagents tailored for processing products generated by the BioXp system. Furthermore, Codex DNA offers Biofoundry Services, a strategic offering that allows clients to outsource the production of endpoint-ready BioXp products such as genes, clones, cell-free amplified DNA, and variant libraries. These services also encompass short oligo ligation assembly enzymatic DNA synthesis, providing a comprehensive solution for clients requiring custom synthetic biology constructs without the need for in-house instrument investment. Codex DNA's diverse customer base spans pharmaceutical firms, academic laboratories, government institutions, contract research organizations (CROs), and other synthetic biology companies worldwide, underscoring its broad impact across the life sciences industry.

What Products and Services Does DNAY Offer?

• Develops and manufactures advanced instruments for synthetic biology, notably the BioXp system.
• Sells reagents and kits, including the proprietary Gibson Assembly brand, essential for DNA synthesis.
• Offers the BioXp system, which converts digital DNA sequences into usable synthetic DNA.
• Provides the BioXp portal, an online platform for designing and assembling DNA sequences into vectors.
• Supplies cloud-based scripts and specialized benchtop reagents for processing BioXp system products.
• Delivers Biofoundry Services for clients to commission endpoint-ready BioXp products like genes, clones, and variant libraries.
• Engages in short oligo ligation assembly enzymatic DNA synthesis as part of its service offerings.
• Aims to accelerate drug discovery and biomanufacturing through automated DNA and mRNA synthesis.

How Does DNAY Make Money?

• Sells proprietary BioXp instruments to pharmaceutical firms, academic labs, and other research institutions.
• Generates recurring revenue through the sale of BioXp kits, reagents, and consumables necessary for instrument operation.
• Offers Biofoundry Services, providing custom synthetic DNA, RNA, and related products on a fee-for-service basis.
• Monetizes its intellectual property, including the Gibson Assembly brand, through product integration and sales.

What Industry Does DNAY Operate In?

Codex DNA, Inc. operates within the dynamic and rapidly expanding synthetic biology sector, which is a segment of the broader Healthcare industry, specifically Medical - Devices. This industry is characterized by continuous innovation aimed at engineering biological systems for various applications, including drug discovery, diagnostics, and biomanufacturing. The market is experiencing significant growth driven by advancements in genomics, increasing demand for personalized medicine, and the need for accelerated research workflows. Codex DNA positions itself by providing automated benchtop instruments and services, such as the BioXp system, which differentiates it from traditional manual synthesis methods. The competitive landscape includes established players in the genomics and life sciences industries, many of whom offer a range of genetic tools, sequencing services, and molecular biology reagents. Codex DNA's focus on automated, rapid DNA and mRNA synthesis places it at the forefront of enabling faster and more efficient biological engineering, catering to a critical need within pharmaceutical and academic research.

Who Are DNAY's Key Customers?

• Pharmaceutical firms globally, utilizing tools for drug discovery and development.
• Academic laboratories worldwide, engaged in fundamental and applied biological research.
• Government institutions, including research agencies and public health organizations.
• Contract Research Organizations (CROs) that provide outsourced research services.
• Other synthetic biology companies seeking advanced synthesis capabilities.

Company Profile

Codex DNA, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Todd R. Nelson MBA,. DNAY has traded publicly since 2021.

Codex DNA, Inc. Financial Trajectory

Codex DNA, Inc. (DNAY) reported $1.6M in revenue for Q3 2024, reflecting 1.0% growth compared to the prior quarter. The company recorded a net loss of $7.3M, with diluted EPS of $-0.41.

How Codex DNA, Inc. Is Valued

Codex DNA, Inc. carries a market capitalization of $38.32M, placing it in the micro-cap category. Relative to its peer group, DNAY's quantitative score of 68/100 is roughly in line with the peer average of 71/100.

Key Financial Metrics

Return on assets is -67.8%, showing how much profit it generates from its asset base. A current ratio of 3.71 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

Codex DNA, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.80 places it in the distress zone, a signal of elevated financial risk.

2/6 beatsEarnings Track Record

Codex DNA, Inc. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 38.4% below estimates on average.

Net buyingInsider Activity

The most recent 8 insider filings for Codex DNA, Inc. break down as 0 sales and 8 purchases. On net that is roughly 6.1M shares acquired (about $14.2M) — insiders putting money in tends to read as conviction.

DNAY Financials

DNAY Latest News

DNAY Analyst Consensus

DNAY MoonshotScore

Common Questions About DNAY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources